New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Carfilnat (Carfilzomib For Injection)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

  • Brand Name- Carfilnat
  • Innovator Brand Name- Kyprolis
  • API- Carfilzomib
  • Packaging- Single Vial
  • Strength- 60 mg
  • Manufacturer Name- Natco Pharma

South Delhi Pharma can facilitate the supply of “Carfilnat (Carfilzomib)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Carfilnat (Carfilzomib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.


Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


What Carfilnat is?

Carfilzomib is an anti-cancer drug indicated to use as a selective proteasome inhibitor for the treatment of: Multiple Myeloma: Patients who have taken at least two prior therapies including treatment with Lenalidomide and Bortezomib.

What Carfilzomib is?

Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.

The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Related Products